180 related articles for article (PubMed ID: 38396173)
21. Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways.
Lu X; Yang F; Chen D; Zhao Q; Chen D; Ping H; Xing N
Int J Biol Sci; 2020; 16(7):1121-1134. PubMed ID: 32174789
[TBL] [Abstract][Full Text] [Related]
22. 1,25-dihydroxyvitamin D(3) and PI3K/AKT inhibitors synergistically inhibit growth and induce senescence in prostate cancer cells.
Axanova LS; Chen YQ; McCoy T; Sui G; Cramer SD
Prostate; 2010 Nov; 70(15):1658-71. PubMed ID: 20583132
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors.
Xu G; Zhang W; Bertram P; Zheng XF; McLeod H
Int J Oncol; 2004 Apr; 24(4):893-900. PubMed ID: 15010827
[TBL] [Abstract][Full Text] [Related]
24. Glaucocalyxin A induces G2/M cell cycle arrest and apoptosis through the PI3K/Akt pathway in human bladder cancer cells.
Lin W; Xie J; Xu N; Huang L; Xu A; Li H; Li C; Gao Y; Watanabe M; Liu C; Huang P
Int J Biol Sci; 2018; 14(4):418-426. PubMed ID: 29725263
[TBL] [Abstract][Full Text] [Related]
25. AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors.
Dunn S; Eberlein C; Yu J; Gris-Oliver A; Ong SH; Yelland U; Cureton N; Staniszewska A; McEwen R; Fox M; Pilling J; Hopcroft P; Coker EA; Jaaks P; Garnett MJ; Isherwood B; Serra V; Davies BR; Barry ST; Lynch JT; Yusa K
Oncogene; 2022 Nov; 41(46):5046-5060. PubMed ID: 36241868
[TBL] [Abstract][Full Text] [Related]
26.
Lu XX; Cao LY; Chen X; Xiao J; Zou Y; Chen Q
Biomed Res Int; 2016; 2016():2476842. PubMed ID: 27822469
[No Abstract] [Full Text] [Related]
27. The main anthocyanin monomer of Lycium ruthenicum Murray induces apoptosis through the ROS/PTEN/PI3K/Akt/caspase 3 signaling pathway in prostate cancer DU-145 cells.
Li ZL; Mi J; Lu L; Luo Q; Liu X; Yan YM; Jin B; Cao YL; Zeng XX; Ran LW
Food Funct; 2021 Feb; 12(4):1818-1828. PubMed ID: 33527955
[TBL] [Abstract][Full Text] [Related]
28. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.
Li J; Davies BR; Han S; Zhou M; Bai Y; Zhang J; Xu Y; Tang L; Wang H; Liu YJ; Yin X; Ji Q; Yu DH
J Transl Med; 2013 Oct; 11():241. PubMed ID: 24088382
[TBL] [Abstract][Full Text] [Related]
29. PTEN Overexpression Cooperates With Lithium to Reduce the Malignancy and to Increase Cell Death by Apoptosis via PI3K/Akt Suppression in Colorectal Cancer Cells.
de Araujo WM; Robbs BK; Bastos LG; de Souza WF; Vidal FC; Viola JP; Morgado-Diaz JA
J Cell Biochem; 2016 Feb; 117(2):458-69. PubMed ID: 26224641
[TBL] [Abstract][Full Text] [Related]
30. PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
Choudhury AD
Prostate; 2022 Aug; 82 Suppl 1():S60-S72. PubMed ID: 35657152
[TBL] [Abstract][Full Text] [Related]
31. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
32. Mammalian target of rapamycin pathway inhibition enhances the effects of 5-aza-dC on suppressing cell proliferation in human gastric cancer cell lines.
Sun D; Toan X; Zhang Y; Chen Y; Lu R; Wang X; Fang J
Sci China C Life Sci; 2008 Jul; 51(7):640-7. PubMed ID: 18622747
[TBL] [Abstract][Full Text] [Related]
33. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines.
Sharrard RM; Maitland NJ
Cell Signal; 2007 Jan; 19(1):129-38. PubMed ID: 16842970
[TBL] [Abstract][Full Text] [Related]
34. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Le B; Powers GL; Tam YT; Schumacher N; Malinowski RL; Steinke L; Kwon G; Marker PC
PLoS One; 2017; 12(3):e0174658. PubMed ID: 28350865
[TBL] [Abstract][Full Text] [Related]
35. Effects of MicroRNA-19b on the Proliferation, Apoptosis, and Migration of Wilms' Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway.
Liu GL; Yang HJ; Liu B; Liu T
J Cell Biochem; 2017 Oct; 118(10):3424-3434. PubMed ID: 28322459
[TBL] [Abstract][Full Text] [Related]
36. S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer.
Nawroth R; Stellwagen F; Schulz WA; Stoehr R; Hartmann A; Krause BJ; Gschwend JE; Retz M
PLoS One; 2011; 6(11):e27509. PubMed ID: 22110663
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
38. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
Tan M; Xu J; Siddiqui J; Feng F; Sun Y
Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
[TBL] [Abstract][Full Text] [Related]
39. Interplay Among PI3K/AKT, PTEN/FOXO and AR Signaling in Prostate Cancer.
Yan Y; Huang H
Adv Exp Med Biol; 2019; 1210():319-331. PubMed ID: 31900915
[TBL] [Abstract][Full Text] [Related]
40. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
